Insulin detemir. Novo Nordisk

Curr Opin Investig Drugs. 2003 Apr;4(4):449-54.

Abstract

Insulin detemir (NN-304) is a soluble, long-acting insulin analog being developed by Novo Nordisk for the potential treatment of type 1 and 2 diabetes. As of February 2003, Novo Nordisk was expecting both US and EU approval in the first half of 2004. In December 2002, Novo Nordisk submitted an NDA to the FDA and an NDS to the Canadian Biologics & Genetics Therapeutic Directorate for the approval of insulin detemir for the treatment of diabetes mellitus.

Publication types

  • Review

MeSH terms

  • Animals
  • Carrier Proteins / adverse effects
  • Carrier Proteins / metabolism
  • Carrier Proteins / pharmacology
  • Carrier Proteins / therapeutic use*
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Diabetes Mellitus, Type 1 / drug therapy*
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Humans
  • Hypoglycemic Agents / adverse effects
  • Hypoglycemic Agents / chemistry
  • Hypoglycemic Agents / metabolism
  • Hypoglycemic Agents / pharmacology
  • Hypoglycemic Agents / therapeutic use*
  • Hypoglycemic Agents / toxicity
  • Insulin / adverse effects
  • Insulin / analogs & derivatives
  • Insulin / metabolism
  • Insulin / pharmacology
  • Insulin / therapeutic use*
  • Insulin Detemir
  • Insulin, Long-Acting
  • Structure-Activity Relationship

Substances

  • Carrier Proteins
  • Hypoglycemic Agents
  • Insulin
  • Insulin, Long-Acting
  • Insulin Detemir